MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
2020 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
172 M |
Market Cap[1] |
$ 2.92 B |
EBITDA (LTM) |
$ -319 M |
P/E (LTM) |
-12.053333 |
P/S (LTM) |
202.037445 |
EPS (LTM) |
-1.5 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Amarin Corporation plc
AMRN
|
$ 11.56 | -5.63 % | $ 4.8 B | Nasdaq Global Market |  Irlanda |
 |
Editas Medicine
EDIT
|
$ 2.53 | -6.99 % | $ 225 M | Nasdaq Global Select Market,SPB | USA |
 |
Agios Pharmaceuticals
AGIO
|
$ 28.28 | -9.88 % | $ 1.64 B | Nasdaq Global Select Market,SPB | USA |
 |
Cue Biopharma
CUE
|
$ 18.09 | -8.82 % | $ 1.71 B | Nasdaq Capital Market,SPB | USA |
 |
Equillium
EQ
|
$ 1.32 | -5.71 % | $ 75.6 M | Nasdaq Global Market | USA |
 |
Black Diamond Therapeutics
BDTX
|
$ 1.68 | -11.84 % | $ 95.5 M | Nasdaq Global Select Market,SPB | USA |
 |
Abeona Therapeutics
ABEO
|
$ 3.91 | -7.35 % | $ 207 M | Nasdaq Capital Market | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
$ 21.23 | -1.12 % | $ 3.57 B | Nasdaq Global Select Market,SPB | USA |
 |
Atossa Therapeutics
ATOS
|
$ 2.04 | -3.77 % | $ 17.6 M | Nasdaq Capital Market | USA |
 |
Cleveland BioLabs, Inc.
CBLI
|
- | -7.31 % | $ 49 M | Nasdaq Capital Market | USA |
 |
Five Prime Therapeutics, Inc.
FPRX
|
- | - | $ 1.77 B | Nasdaq Global Select Market | USA |
 |
ADC Therapeutics SA
ADCT
|
$ 1.64 | -3.49 % | $ 208 M | NYSE |  Schweiz |
 |
Harmony Biosciences Holdings
HRMY
|
$ 32.46 | -5.7 % | $ 1.87 B | Nasdaq Global Select Market | USA |
 |
Ardelyx
ARDX
|
$ 2.98 | -9.57 % | $ 718 M | Nasdaq Global Market | USA |
 |
Akebia Therapeutics
AKBA
|
$ 0.43 | -38.22 % | $ 111 M | Nasdaq Global Market | USA |
 |
Alector
ALEC
|
$ 2.08 | -8.99 % | $ 214 M | Nasdaq Global Select Market,SPB | USA |
 |
ALX Oncology Holdings
ALXO
|
$ 1.14 | -16.54 % | $ 61.2 M | Nasdaq Global Select Market,SPB | USA |
 |
Amneal Pharmaceuticals
AMRX
|
$ 19.49 | -2.33 % | $ 6.11 B | NYSE | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 3.65 | -10.1 % | $ 699 M | Nasdaq Global Select Market |  Canada |
 |
Agenus
AGEN
|
$ 6.42 | -7.89 % | $ 191 M | Nasdaq Capital Market | USA |
 |
AbCellera Biologics
ABCL
|
$ 11.11 | -9.52 % | $ 3.32 B | Nasdaq Global Select Market | Canada |
 |
Artelo Biosciences
ARTL
|
$ 2.12 | -8.77 % | $ 401 K | Nasdaq Global Select Market | USA |
 |
Immatics N.V.
IMTX
|
$ 6.2 | -10.35 % | $ 759 M | Nasdaq Global Select Market |  Germany |
 |
Aptevo Therapeutics
APVO
|
$ 1.24 | -9.49 % | $ 391 K | Nasdaq Capital Market | USA |
 |
Aligos Therapeutics
ALGS
|
$ 4.58 | -8.76 % | $ 45.3 M | Nasdaq Global Select Market | USA |
 |
Aclaris Therapeutics
ACRS
|
$ 3.62 | -1.63 % | $ 444 M | Nasdaq Global Select Market | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
$ 26.8 | 0.32 % | $ 4.07 B | Nasdaq Global Select Market,SPB | USA |
 |
Cellectar Biosciences
CLRB
|
$ 1.16 | -6.1 % | $ 3.03 M | Nasdaq Capital Market | USA |
|
Larimar Therapeutics
LRMR
|
$ 2.31 | -16.3 % | $ 192 M | Nasdaq Global Market | USA |
 |
Biofrontera AG
BFRA
|
- | -8.24 % | $ 105 M | Nasdaq Capital Market | Germany |
 |
Catabasis Pharmaceuticals, Inc.
CATB
|
- | -6.97 % | $ 657 M | Nasdaq Global Market | USA |
 |
Capricor Therapeutics
CAPR
|
$ 8.6 | -3.64 % | $ 400 M | Nasdaq Capital Market | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 27.55 | -1.68 % | $ 1.29 B | Nasdaq Global Select Market | USA |
 |
China Biologic Products Holdings, Inc.
CBPO
|
- | 1.68 % | $ 4.65 B | Nasdaq Global Select Market |  China |
 |
Aquestive Therapeutics
AQST
|
$ 3.66 | -3.82 % | $ 391 M | Nasdaq Global Market | USA |
 |
Jaguar Health
JAGX
|
$ 0.4 | -19.71 % | $ 933 K | Nasdaq Capital Market | USA |
 |
Arvinas
ARVN
|
$ 6.56 | -11.66 % | $ 465 M | Nasdaq Global Select Market,SPB | USA |
 |
Cerus Corporation
CERS
|
$ 2.13 | -12.01 % | $ 406 M | Nasdaq Global Market | USA |
 |
Beam Therapeutics
BEAM
|
$ 25.84 | -7.03 % | $ 2.56 B | Nasdaq Global Select Market | USA |
 |
Moderna
MRNA
|
$ 241.1 | -6.69 % | $ 93.8 B | Nasdaq Global Select Market,SPB | USA |
 |
Fortress Biotech
FBIO
|
$ 1.83 | -7.11 % | $ 51.1 M | Nasdaq Capital Market | USA |
 |
Inhibrx
INBX
|
$ 80.4 | -7.34 % | $ 3.79 B | Nasdaq Global Select Market | USA |
 |
Entera Bio Ltd.
ENTX
|
$ 3.0 | -3.54 % | $ 139 M | Nasdaq Capital Market |  Israel |
 |
Flexion Therapeutics, Inc.
FLXN
|
- | - | $ 459 M | Nasdaq Global Market | USA |
 |
Legend Biotech Corporation
LEGN
|
$ 22.52 | -1.1 % | $ 8.3 B | Nasdaq Global Select Market | USA |
 |
CytomX Therapeutics
CTMX
|
$ 2.14 | -8.94 % | $ 295 M | Nasdaq Global Select Market | USA |
 |
Krystal Biotech
KRYS
|
$ 300.08 | -3.46 % | $ 8.69 B | Nasdaq Global Market,SPB | USA |
 |
Kura Oncology
KURA
|
$ 6.93 | -9.0 % | $ 608 M | Nasdaq Global Select Market | USA |
 |
Inhibikase Therapeutics
IKT
|
$ 1.45 | -7.67 % | $ 143 M | Nasdaq Capital Market | USA |
 |
Heron Therapeutics
HRTX
|
$ 0.28 | -6.8 % | $ 46.7 M | Nasdaq Global Select Market,SPB | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.